The payment will be made under the terms of the amended and restated supply agreement signed in August 2007.
Stimuvax (BLP25 liposome vaccine) is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. Merck KGaA currently is conducting a global Phase III trial to evaluate patients with documented unresectable non-small cell lung cancer.